Advanced Biomed INC. (ADVB) — SEC Filings

Overview

Advanced Biomed INC. (ADVB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: Advanced Biomed Inc. announced on December 23, 2025, the completion of an acquisition. The company also entered into a material definitive agreement related to this transaction. Further details regarding financial statements and exhibits are included in the filing.

Sentiment Summary

Across 18 filings, the sentiment breakdown is: 2 bearish, 15 neutral, 1 mixed. The dominant filing sentiment for Advanced Biomed INC. is neutral.

Filing Type Overview

Advanced Biomed INC. (ADVB) has filed 6 8-K, 3 10-Q, 1 10-K, 1 S-1, 7 S-1/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (18)

• Advanced Biomed Completes Acquisition — 8-K · Dec 30, 2025 Risk: medium
  Advanced Biomed Inc. announced on December 23, 2025, the completion of an acquisition. The company also entered into a material definitive agreement related to
• Advanced Biomed's Q3 Loss Widens Amid R&D Spend — 10-Q · Nov 19, 2025 Risk: high
  Advanced Biomed Inc. (ADVB) reported a net loss of $386,901 for the three months ended September 30, 2025, a 45.7% increase from the $265,580 net loss in the sa
• Advanced Biomed Eyes Global Expansion Amidst Regulatory Hurdles — 10-K · Oct 8, 2025 Risk: high
  Advanced Biomed Inc. (ADVB) reported a market value of approximately $4.43 million as of June 30, 2025, with 21,640,000 shares of common stock outstanding as of
• Advanced Biomed Inc. Files 8-K Report — 8-K · Sep 19, 2025 Risk: low
  On September 19, 2025, Advanced Biomed Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial stateme
• Advanced Biomed Faces Delisting Concerns — 8-K · Jul 24, 2025 Risk: high
  Advanced Biomed Inc. filed an 8-K on July 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indic
• Advanced Biomed Files S-1 for Public Offering, Signals Taiwan-US Operations — S-1 · Jul 23, 2025 Risk: high
  Advanced Biomed Inc. (ADVB) filed an S-1 registration statement on July 23, 2025, indicating its intent for a public offering of securities. The company, incorp
• Advanced Biomed Inc. Files Material Definitive Agreement 8-K — 8-K · Jun 6, 2025 Risk: medium
  On June 6, 2025, Advanced Biomed Inc. filed an 8-K report detailing a material definitive agreement. The company, incorporated in Nevada with its principal exec
• Advanced Biomed Inc. Reports Director and Officer Changes — 8-K · May 28, 2025 Risk: low
  Advanced Biomed Inc. filed an 8-K on May 28, 2025, reporting changes effective May 23, 2025. The filing covers the departure and election of directors, appointm
• Advanced Biomed Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  Advanced Biomed Inc. filed its quarterly report on March 31, 2025. The company, incorporated in Nevada, operates in the medical laboratories sector. Its princip
• Advanced Biomed Inc. Files Q4 2024 10-Q — 10-Q · Apr 15, 2025 Risk: low
  Advanced Biomed Inc. filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Nevada and headquartered in Reno, operates in
• Advanced Biomed Inc. Files 8-K for Material Agreement — 8-K · Mar 10, 2025 Risk: medium
  Advanced Biomed Inc. filed an 8-K on March 10, 2025, reporting a material definitive agreement entered into on March 5, 2025. The filing also includes Regulatio
• Advanced Biomed Inc. Files S-1/A Amendment — S-1/A · Feb 7, 2025 Risk: medium
  Advanced Biomed Inc. filed an S-1/A amendment on February 7, 2025, for its registration statement. The company, incorporated in Nevada, has its principal execut
• Advanced Biomed Inc. Files S-1/A Amendment — S-1/A · Jan 27, 2025 Risk: medium
  Advanced Biomed Inc. filed an S-1/A amendment on January 27, 2025, for its registration statement. The company, incorporated in Nevada, has its principal execut
• Advanced Biomed Inc. Files S-1/A Amendment — S-1/A · Jan 7, 2025 Risk: medium
  Advanced Biomed Inc. filed an S-1/A amendment on January 7, 2025, for its registration statement. The company, incorporated in Nevada, operates in the medical l
• Advanced Biomed Inc. Amends S-1 Registration — S-1/A · Oct 28, 2024 Risk: medium
  Advanced Biomed Inc. filed an S-1/A amendment on October 28, 2024, for its registration statement under the Securities Act of 1933. The company, incorporated in
• Advanced Biomed Inc. Files Amendment to S-1 Registration Statement — S-1/A · Feb 8, 2024 Risk: low
  Advanced Biomed Inc. (ADVB) filed a Amended IPO Registration (S-1/A) with the SEC on February 8, 2024. Advanced Biomed Inc. filed an amendment (S-1/A) to its re
• Advanced Biomed Inc. Files Amendment to S-1 Registration Statement — S-1/A · Jan 19, 2024 Risk: medium
  Advanced Biomed Inc. (ADVB) filed a Amended IPO Registration (S-1/A) with the SEC on January 19, 2024. Advanced Biomed Inc. filed an amendment (S-1/A) to its re
• Advanced Biomed Inc. Files Amendment to S-1 Registration Statement — S-1/A · Jan 9, 2024 Risk: low
  Advanced Biomed Inc. (ADVB) filed a Amended IPO Registration (S-1/A) with the SEC on January 9, 2024. Advanced Biomed Inc. filed an amendment (S-1/A) to its reg

Risk Profile

Risk Assessment: Of ADVB's 18 recent filings, 4 were flagged as high-risk, 8 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Advanced Biomed INC.'s most recent 10-Q filing (Nov 19, 2025):

• Net Income: -$386,901
• EPS: -$0.02
• Debt-to-Equity: 1.07
• Cash Position: $2,656,519
• Total Assets: $6,242,970
• Total Debt: $3,238,846

Key Executives

• Dr. Yi Lu
• Chen-Yi Lee
• Dr. Hung To Pau
• Fang Liu, Esq.
• Fang Liu
• William S. Rosenstadt, Esq.
• Mengyi “Jason” Ye, Esq.
• William S. Rosenstadt
• Mengyi "Jason" Ye

Industry Context

Advanced Biomed Inc. operates in the oncology product development and commercialization sector. This is a highly competitive and research-intensive field, requiring significant capital investment in R&D. The company's focus on Taiwan and China suggests a strategy to leverage these markets for growth, though it also introduces specific regional risks.

Top Tags

sec-filing (4) · registration (3) · S-1/A (3) · Registration Statement (3) · Advanced Biomed Inc. (3) · Biotechnology (2) · IPO (2) · regulatory-filing (2) · financials (2) · Emerging Growth Company (2)

Key Numbers

• Net Loss: $386,901 — for the three months ended September 30, 2025, a 45.7% increase from prior year
• Total Operating Expenses: $523,914 — for the three months ended September 30, 2025
• Research and Development Expenses: $235,992 — for the three months ended September 30, 2025, up 29.9%
• Cash: $2,656,519 — as of September 30, 2025, a decrease of $247,396 from June 30, 2025
• Net IPO Proceeds: $5.49 million — raised from the initial public offering on March 7, 2025
• Shares Outstanding: 21,640,000 — as of November 19, 2025
• Cash Used in Operating Activities: $610,342 — for the three months ended September 30, 2025
• Total Stockholders' Equity: $3,004,124 — as of September 30, 2025
• Total Liabilities: $3,238,846 — as of September 30, 2025
• Aggregate market value of non-affiliate common stock: $4.43 million — as of June 30, 2025
• Shares of outstanding Common Stock: 21,640,000 — as of October 8, 2025
• Shares offered in Initial Public Offering: 1,640,000 — completed on March 7, 2025
• Per share price in Initial Public Offering: $4.00 — completed on March 7, 2025
• Sensitivity of A+LCGuard in Shanghai Pulmonary Hospital study: 96% — achieved in 123 case studies
• Specificity of A+LCGuard in Shanghai Pulmonary Hospital study: 99.9% — achieved in 123 case studies

Forward-Looking Statements

• {"claim":"Advanced Biomed Inc. will complete its initial public offering within the next 6-12 months.","entity":"Advanced Biomed Inc.","targetDate":"2025-02-08","confidence":"medium"}

Frequently Asked Questions